Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets

Diabetologia

Volumn 54, Issue 8, 2011, Pages 2152-2163

  Luther, J M ^a   Luo, P ^a   Kreger, M T ^a   Brissova, M ^a   Dai, C ^a   Whitfield, T T ^b   Kim, H S ^c   Wasserman, D H ^a,d   Powers, A C ^a,d,e   Brown, N J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Aldosterone synthase; Diabetes mellitus; Glucose clamp technique; Insulin; Mineralocorticoid receptor; Pancreatic beta cells; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; C PEPTIDE; EPLERENONE; GLUCOSE; INSULIN; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; POTASSIUM; RENIN; SUPEROXIDE DISMUTASE; TEMPOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CANCER CELL CULTURE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GONAD; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; SODIUM INTAKE;

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; BLOOD GLUCOSE; CELL LINE; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL;

EID: 79960916860     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2158-9     Document Type: Article

References (50)

1. Rocha R, Stier CT Jr, Kifor I et al (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878
2. Goodfriend TL, Egan BM, Kelley DE (1999) Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 60:401-405 (Pubitemid 29401800)
3. Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48:239-245 (Pubitemid 44309818)
4. Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116:984-992 (Pubitemid 47329563)
5. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304:930-933 (Pubitemid 11101080)
6. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K (2004) Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43:358-363 (Pubitemid 38174139)
7. Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273:1135-1143
8. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30:2349-2354 (Pubitemid 47359046)
9. Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457-3463 (Pubitemid 44402119)
10. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846 (Pubitemid 46024990)
11. Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 25:2125-2130 (Pubitemid 47476311)
12. Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551-1562 (Pubitemid 44550032)
13. McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477-1490
14. Makhanova N, Lee G, Takahashi N et al (2006) Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol 290:F61-F69
15. Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ (2009) Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 150:2229-2236
16. Lee G, Makhanova N, Caron K et al (2005) Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 146:2650-2656 (Pubitemid 40695567)
17. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390-397 (Pubitemid 43343268)
18. Fueger PT, Hess HS, Bracy DP et al (2004) Regulation of insulin-stimulated muscle glucose uptake in the conscious mouse: role of glucose transport is dependent on glucose phosphorylation capacity. Endocrinology 145:4912-4916 (Pubitemid 39551107)
19. Berglund ED, Li CY, Poffenberger G et al (2008) Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 57:1790-1799
20. Brissova M, Shiota M, Nicholson WE et al (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225-11232 (Pubitemid 34952885)
21. Miyazaki J, Araki K, Yamato E et al (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127:126-132 (Pubitemid 20228111)
22. Brown NJ (2003) Eplerenone: cardiovascular protection. Circulation 107:2512-2518 (Pubitemid 36605237)
23. Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27-31 (Pubitemid 38596625)
24. Gomez-Sanchez CE, de Rodriguez AF, Romero DG et al (2006) Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology 147:1343-1348 (Pubitemid 43244368)
25. Uehara S, Tsuchida M, Kanno T, Sasaki M, Nishikibe M, Fukamizu A (2003) Late-onset obesity in mice transgenic for the human renin gene. Int J Mol Med 11:723-727
26. Gratze P, Boschmann M, Dechend R et al (2009) Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension 53:516-523
27. Hitomi H, Kiyomoto H, Nishiyama A et al (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50:750-755 (Pubitemid 47442741)
28. Lastra G, Whaley-Connell A, Manrique C et al (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TGmRen227 rat. Am J Physiol Endocrinol Metab 295:E110-E116
29. Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127-133 (Pubitemid 28088387)
30. Leung PS, Chan WP, Wong TP, Sernia C (1999) Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 160:13-19 (Pubitemid 29044563)
31. Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64:2537-2565 (Pubitemid 39591650)
32. Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 108:21-25 (Pubitemid 30160431)
33. Voiculescu A, Hollenbeck M, Kutkuhn B, Grabensee B, Plum J (2003) Successful treatment of renovascular hypertension has no effect on insulin sensitivity. Eur J Clin Investig 33:848-854 (Pubitemid 37215039)
34. Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638-1644
35. Pierluissi J, Navas FO, Ashcroft SJ (1986) Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 29:119-121 (Pubitemid 16162755)
36. Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ (2008) Research resource: nuclear hormone receptor expression in the endocrine pancreas. Mol Endocrinol 22:2353-2363
37. Lemarie CA, Simeone SM, Nikonova A et al (2009) Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105:852-859
38. Boldyreff B, Wehling M (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 18:1693-1695 (Pubitemid 37098534)
39. Hirasawa G, Sasano H, Ki T et al (1997) Colocalization of 11β-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 82:3859-3863 (Pubitemid 27509383)
40. Losel R, Schultz A, Boldyreff B, Wehling M (2004) Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 69:575-578 (Pubitemid 39013490)
41. Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458:231-246
42. Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6:261-273
43. Drews G, Krippeit-Drews P, Dufer M (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460:703-718
44. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC (2007) Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21:2185-2194 (Pubitemid 47026453)
45. Shimamoto K, Shiiki M, Ise T et al (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8:755-759 (Pubitemid 24319387)
46. Weinberger MH, White WB, Ruilope LM et al (2005) Effects of eplerenone vs losartan in patients with low-renin hypertension. Am Heart J 150:426-433 (Pubitemid 41317608)
47. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:762-768
48. Arase Y, Suzuki F, Suzuki Y et al (2009) Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 81:1584-1590
49. Strauch B, Widimsky J, Sindelka G, Skrha J (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52:503-506 (Pubitemid 37039916)
50. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831-838